Floatz logo

apd356

Digestive System Carcinoma

Ohio State University Comprehensive Cancer CenterPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Digestive System Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2B
Irinotecan
National Cancer Institute (NCI)
Phase 1/2CCC
Kras Tcr-Transduced Pbl
National Cancer Institute (NCI)
Phase 2CCC
Fludarabine
National Cancer Institute (NCI)
Phase 2CCC
Trifluridine
Emory University
Phase 1/2CCC

View all 25 →

Same molecule, other indications

apd356 is also rated in:

obesity disorderDormant
BB
Indicative ·
66 / 100
View asset →
cardiovascular disorderDormant
B
Indicative ·
63 / 100
View asset →
nicotine dependenceDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →